ReviewThe FEBS journal2025
Posttranslational modifications of phosphodiesterase type 4 enzymes represent novel points for therapeutic targeting.
Madihah Hussain et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it